Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
|
|
PROGENICS PHARMACEUTICALS INC (PGNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/22/2020 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : June 19, 2020 Progenics Pharmaceuticals, Inc. Delaware 000-23143 13-3379479 One World Trade Center, 47th Floor, New York, New York 10007 Registrant's telephone number, including area code: 975-2500 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchang...",
"Fourth Amended and Restated Certificate of Incorporation of Progenics Pharmaceuticals, Inc., effective June 19, 2020",
"Amended and Restated Bylaws of Progenics, effective June 19, 2020",
"Lantheus Completes Merger with Progenics" |
|
| 11/12/2013 |
8-K
| Quarterly results, Appointed a new director |
| 03/09/2011 |
8-K
| Appointed a new director |
| 02/04/2009 |
8-K
| Form 8-K -- Current report |
|
|